Ipilimumab: tested in a combination
412 studies: another drug in the study is under test too. Page 4 of 5. Open to participants first (80), then studies with results posted, then the rest; newest registration first within each.
- Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based ChemotherapyActive, not recruitingNCT03670056Phase 2Report a problem
- Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsActive, not recruitingNCT03650894Phase 2Report a problem
- Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric CancerCompletedNCT03647969Phase 2Report a problem
- A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and NeckCompletedNCT03620123Phase 2Report a problem
- Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing SurgerySuspendedNCT03604991Phase 2/3Report a problem
- Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III MeningiomaActive, not recruitingNCT03604978Phase 1/2Report a problem
- Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT03600155Phase 1Report a problem
- Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)CompletedNCT03591731Phase 2Report a problem
- Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast CancerActive, not recruitingNCT03546686Phase 2Report a problem
- Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular MelanomaActive, not recruitingNCT03528408Phase 2Report a problem
- A Study of CS1002 in Subjects with Advanced Solid TumorsCompletedNCT03523819Phase 1Report a problem
- A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for ChemotherapyActive, not recruitingNCT03520491Phase 2Report a problem
- Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)CompletedNCT03510871Phase 2Report a problem
- Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer PatientsTerminatedNCT03509584Phase 1Report a problem
- Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisCompletedNCT03508570Phase 1Report a problem
- Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate CancerWithdrawnNCT03477864Phase 1Report a problem
- Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancErCompletedNCT03469960Phase 3Report a problem
- Immunotherapy + Radiation in Resectable Soft Tissue SarcomaCompletedNCT03463408Early Phase 1Report a problem
- Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for RecurrenceActive, not recruitingNCT03443856Phase 2Report a problem
- Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal CancerTerminatedNCT03437200Phase 2Report a problem
- A Longitudinal Assessment of Tumor Evolution in Patients With Brain CancerCompletedNCT03425292Phase 1Report a problem
- A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell CancerCompletedNCT03416244Phase 2Report a problem
- Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric AdenocarcinomaCompletedNCT03409848Phase 2Report a problem
- Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast CancerCompletedNCT03409198Phase 2Report a problem
- Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapyCompletedNCT03387761Phase 1Report a problem
- BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasActive, not recruitingNCT03355976Phase 2Report a problem
- Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC PatientsCompletedNCT03351361Phase 3Report a problem
- iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and IpilimumabActive, not recruitingNCT03350126Phase 2Report a problem
- Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer PatientsTerminatedNCT03342417Phase 2Report a problem
- Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsActive, not recruitingNCT03333616Phase 2Report a problem
- Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before SurgeryActive, not recruitingNCT03307616Phase 2Report a problem
- Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCLCompletedNCT03305445Phase 1Report a problem
- Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03297593Phase 2Report a problem
- Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic MelanomaWithdrawnNCT03297463Phase 1/2Report a problem
- Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT03283046Phase 1Report a problem
- A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian CancerCompletedNCT03245892Phase 1Report a problem
- Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal MelanomaStatus unknownNCT03241186Phase 2Report a problem
- Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung CancerActive, not recruitingNCT03223155Phase 1Report a problem
- Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaWithdrawnNCT03220009Phase 2Report a problem
- Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell CarcinomaStatus unknownNCT03219775Phase 2Report a problem
- Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)Status unknownNCT03219671Phase 2Report a problem
- Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver CancerTerminatedNCT03203304Phase 1Report a problem
- Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)Status unknownNCT03177239Phase 2Report a problem
- Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck CancerCompletedNCT03162731Early Phase 1Report a problem
- Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent NivolumabWithdrawnNCT03149159Phase 2Report a problem
- SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma PatientsWithdrawnNCT03126461Phase 2Report a problem
- Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and NivolumabCompletedNCT03126331Phase 2Report a problem
- A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyActive, not recruitingNCT03122522Phase 2Report a problem
- Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic CancerActive, not recruitingNCT03104439Phase 2Report a problem
- Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal CarcinomaActive, not recruitingNCT03097939Phase 2Report a problem
- Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung CancerTerminatedNCT03091491Phase 2Report a problem
- BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung CancerCompletedNCT03083691Phase 2Report a problem
- Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCCCompletedNCT03075423Phase 2Report a problem
- Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic SignatureActive, not recruitingNCT03061539Phase 2Report a problem
- Ipilimumab and Nivolumab in the Treatment of Malignant Pleural MesotheliomaCompletedNCT03048474Phase 2Report a problem
- A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung CancerWithdrawnNCT03048136Phase 3Report a problem
- ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck CarcinomaCompletedNCT03003637Phase 1/2Report a problem
- A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial CarcinomaStatus unknownNCT02982486Phase 2Report a problem
- Optimal Neo-adjuvant Combination Scheme of Ipilimumab and NivolumabActive, not recruitingNCT02977052Phase 2Report a problem
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerCompletedNCT02960906Phase 2Report a problem
- Study to Nivolumab Following Preoperative ChemoradiotherapyStatus unknownNCT02948348Phase 1/2Report a problem
- A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma MacrometastasesCompletedNCT02941744Phase 1/2Report a problem
- A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare CancersCompletedNCT02923934Phase 2Report a problem
- Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell CarcinomaCompletedNCT02917772Phase 2Report a problem
- Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver MetastasesStatus unknownNCT02913417Phase 1/2Report a problem
- Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02880020Phase 2Report a problem
- Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer PatientsCompletedNCT02866383Phase 2Report a problem
- A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic MelanomaCompletedNCT02857569Phase 1/2Report a problem
- Single Agent and Combined Inhibition After Allogeneic Stem Cell TransplantTerminatedNCT02846376Phase 1Report a problem
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2Report a problem
- Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade GliomasCompletedNCT02829931Phase 1Report a problem
- Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab AloneWithdrawnNCT02736123Phase 1/2Report a problem
- Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) PatientsCompletedNCT02716272Phase 2Report a problem
- Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung CancerActive, not recruitingNCT02696993Phase 1/2Report a problem
- Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal MelanomaCompletedNCT02626962Phase 2Report a problem
- Nivo/Ipi Combination Therapy in Symptomatic Brain MetastasesTerminatedNCT02621515Phase 2Report a problem
- Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic SyndromeActive, not recruitingNCT02530463Phase 2Report a problem
- Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NEDCompletedNCT02523313Phase 2Report a problem
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1Report a problem
- A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain MetastasisStatus unknownNCT02460068Phase 3Report a problem
- Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma PatientsActive, not recruitingNCT02437279Phase 1Report a problem
- Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain MetastasesActive, not recruitingNCT02374242Phase 2Report a problem
- Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT02311920Phase 1Report a problem
- Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV MelanomaTerminatedNCT02200562Phase 1Report a problem
- Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs ObservationCompletedNCT02196961Phase 2Report a problem
- Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic MalignanciesTerminatedNCT02070406Phase 1Report a problem
- Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical ProstatectomyCompletedNCT02020070Phase 2Report a problem
- Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerCompletedNCT01998126Phase 1Report a problem
- Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma PatientsTerminatedNCT01988077Phase 2Report a problem
- Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01940809Phase 1Report a problem
- Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck CancerCompletedNCT01935921Phase 1Report a problem
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaActive, not recruitingNCT01896999Phase 1/2Report a problem
- Sipuleucel-T and Ipilimumab for Advanced Prostate CancerCompletedNCT01832870Phase 1Report a problem
- Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1Report a problem
- Ipilimumab and Lenalidomide in Advanced CancerCompletedNCT01750983Phase 1Report a problem
- Ipilimumab and Imatinib Mesylate in Advanced CancerCompletedNCT01738139Phase 1Report a problem
- Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT01729806Phase 1Report a problem
- Study of Ipilimumab in the Immune SystemCompletedNCT01715077Not applicableReport a problem
- Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV MelanomaActive, not recruitingNCT01676649Phase 2Report a problem
- A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV MelanomaCompletedNCT01672450Phase 1Report a problem